Promomed Group and the Department of Investment and Industrial Policy of the city of Moscow signed an agreement in the field of biotechnology development
Today Promomed Group and the Moscow Department of Investment and Industrial Policy signed a cooperation agreement at the XXVI St. Petersburg International Economic Forum (SPIEF) in the interests of developing new high-tech sectors of the economy, creating new jobs in modern high-tech industries and in innovative companies.
This Agreement includes creation of necessary conditions for the Promomed Group’s member Artsellens to conduct industrial and production activities in the special economic zone “Technopolis Moscow”. At the Pechatniki site of Technopolis Moscow, the company plans to create a modern research laboratory with a pilot production site for the development of modern drugs, including original ones, and scaling of technological processes; at the Alabushevo site the production of original domestic biologics will be launched.
“With the support of the Moscow Government at the Technopolis site, Promomed Group is creating a center for a full cycle production of biotechnological drugs of the latest generations. It is here that we plan to develop our new line of biotechnological substances,” Petr Bely, Chairman of the Board of Directors of Promomed Group, comments on the Agreement. “We are very grateful to the Government of Moscow and personally to the Mayor of Moscow Sergey Sobyanin for supporting this fundamentally important project for domestic medicine. For pharmaceutical independence, we need our own next-in-class and first-in-class innovative drugs. They are needed to move us forward. Today's agreement between the Moscow Government and Promomed Group is a significant step in this direction. We will do everything we can to bring the latest biopharmaceuticals to our doctors as soon as possible and to strengthen the export potential of our Motherland.”
Vladislav Ovchinsky, head of the Department of Investment and Industrial Policy of the city of Moscow, comments: “New production will become a part of the pharmaceutical cluster of the special economic zone. The research unit will be located at the Pechatniki site, the Alabushevo site will host the production. A plot of 3.2 hectares was allocated for the construction of the enterprise. It is planned to create more than 400 jobs. Investments in the project will amount to about 4.3 billion rubles.”
The project will begin with the production of biosimilars of technologically sophisticated foreign drugs for the most important diseases. At the second stage, a technological base will be created for the development of original domestic biologics.
For reference:
Artsellens (member of Promomed Group) is engaged in the research, development and production of medicines. Founded in 2023, the company is the successor of biotechnological production based on the Biokhimik plant in Saransk.
The area of the research unit in Pechatniki is 4,700 m2; the area of the production site at the Alabushevo SEZ is 3.2 ha.
The total production capacity at Artsellens is estimated at 150 kg of substance per year or about 750 thousand vials of the drug product. It is planned that at the first stage the capacity of the pilot production will be about 250 thousand vials of the drug product per year.
The project will create over 400 new jobs for highly qualified specialists: at least 115 jobs at the Pechatniki site and at least 295 jobs at the Alabushevo site.
